KRAS and non-small cell lung carcinoma: A higher overall mutation burden and less conserved co-alteration landscape may partly explain this disparity in clinical activity, and it remains to be seen how distinct co-alteration patterns in KRAS G12C-mutant NSCLC across ancestries may influence the activity of KRAS G12C inhibitors.